| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner | Director, Former 10% Owner
7 companies
Akkaraju Srinivas is a Director at ALMS, with reported holdings spanning 7 companies. Recent filings cover 44 purchases and 11 sales. Those positions are worth an estimated $64.8M at current prices.
Our model assigns Akkaraju Srinivas a strong insider score of 81/100, based on 23 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +59.9%.
Akkaraju Srinivas's largest disclosed position is in ALMS as Director, worth about $52.5M. Net of sales, the recent Form 4 record there shows accumulation of 3,064,368 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | ALMS Alumis Inc. | Director | Buy | 276,179 | $5.25 | $1,449,939.75 | New | +385.4% | - | |
| Oct 7, 2025 | SRRK Scholar Rock Holding Corp | Director | Buy | 29,599 | $39.92 | $1,181,633.67 | +5.9% | +8.3% | - | |
| Oct 6, 2025 | SRRK Scholar Rock Holding Corp | Director | Buy | 500,439 | $37.58 | $18,807,352.19 | New | +7.4% | - | |
| Sep 4, 2025 | MLYS Mineralys Therapeutics, Inc. | Director | Buy | 588,235 | $25.50 | $14,999,992.50 | New | +18.4% | - | |
| May 5, 2025 | ALMS Alumis Inc. | Director | Buy | 320,290 | $4.61 | $1,477,311.98 | +9.8% | -7.0% | +493.9% | |
| Mar 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Director | Buy | 600,000 | $13.50 | $8,100,000.00 | +11.8% | +15.2% | +94.0% | |
| Oct 7, 2024 | SRRK Scholar Rock Holding Corp | Director | Sell | 1,175,713 | $29.25 | $34,385,672.50 | -17.3% | +25.0% | +15.2% | |
| Dec 21, 2023 | SYRS Syros Pharmaceuticals, Inc. | Director | Buy | 904,977 | $4.42 | $3,999,998.34 | +102.7% | - | - | |
| Oct 16, 2023 | SRRK Scholar Rock Holding Corp | Director, 10% Owner | Buy | 2,189,781 | $6.85 | $14,999,999.85 | +47.6% | +92.6% | +245.5% | |
| Feb 14, 2023 | MLYS Mineralys Therapeutics, Inc. | Director, 10% Owner | Buy | 937,500 | $16.00 | $15,000,000.00 | +26.2% | -10.1% | -19.3% |